Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

FLT3 Mutations in Pediatric Acute Promyelocytic Leukemia; A Report from the Children's Oncology Group AAML0631 Trial

Matthew A. Kutny, MD, Todd A. Alonzo, PhD, Robert Gerbing, BS, Yi-Cheng Wang, Cecilia Fu, MD, Alan S. Gamis, MD MPH, E. Anders Kolb, MD, James H. Feusner, MD, John Gregory, Jr., MD, Soheil Meshinchi, MD PhD

Blood (2016) 128 (22): 2884.

https://doi.org/10.1182/blood.V128.22.2884.2884

Published: 2016

Journal Articles

Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631

Matthew A. Kutny, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Cecilia Fu, MD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH, James H. Feusner, MD, John Gregory, Jr., MD

Blood (2015) 126 (23): 219.

https://doi.org/10.1182/blood.V126.23.219.219

Published: 2015

Journal Articles

Effect of Young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance)

Matthew A. Kutny, MD, Susan Geyer, PhD, Kristina M Laumann, BA, John Gregory, MD, Cheryl L. Willman, MD, Wendy Stock, MD, Richard A. Larson, Bayard L. Powell, MD, James H. Feusner, MD

Blood (2014) 124 (21): 2301.

https://doi.org/10.1182/blood.V124.21.2301.2301

Published: 2014

Journal Articles

A Comparison of Outcomes Between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance)

Matthew A. Kutny, MD, Susan Geyer, PhD, Kristina M Laumann, BA, John Gregory, MD, Cheryl L. Willman, MD, Wendy Stock, MD, Richard A. Larson, Bayard L. Powell, MD, James H. Feusner, MD

Blood (2014) 124 (21): 2306.

https://doi.org/10.1182/blood.V124.21.2306.2306

Published: 2014

Journal Articles

Evaluation of ISTH DIC Score to Predict Significant Bleeding and Thrombosis Events in Pediatric Acute Promyelocytic Leukemia; A Report from the Children’s Oncology Group AAML0631 Trial

Matthew A. Kutny, MD, Madhvi Rajpurkar, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Alan S. Gamis, MD MPH, James H. Feusner, MD, John Gregory, MD

Blood (2014) 124 (21): 3669.

https://doi.org/10.1182/blood.V124.21.3669.3669

Published: 2014

Journal Articles

Arsenic Trioxide Is a Well Tolerated Consolidation Regimen in Children with Newly Diagnosed Acute Promyelocytic Leukemia; Toxicity Results of the Children’s Oncology Group AAML0631 Trial

Matthew A. Kutny, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Cecilia Fu, MD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH, James H. Feusner, MD, John Gregory, MD

Blood (2014) 124 (21): 985.

https://doi.org/10.1182/blood.V124.21.985.985

Published: 2014

Journal Articles

Obesity Does Not Affect the Recurrence Free Survival Rates in Children Less Than 20 Years of Age in Acute Promyelocytic Leukemia (APL)

Ji Heon (Paul) Lee, MDPhD, Alfred W. Rademaker, PhD, Bayard L. Powell, MD, Susan Geyer, PhD, Richard A. Larson, John Gregory, MD, Nobuko Hijiya, MD, James H. Feusner, MD

Blood (2014) 124 (21): 957.

https://doi.org/10.1182/blood.V124.21.957.957

Published: 2014

Journal Articles

A Pilot Study to Assess Alterations in Trace Element Status in Pediatric Patients with Malignancies.

Jong Chung, MD, Ellen B Fung, PhD, RD, CCD, James H. Feusner, M.D.

Blood (2012) 120 (21): 3183.

https://doi.org/10.1182/blood.V120.21.3183.3183

Published: 2012

Journal Articles

Treatment-influenced associations of PML-RAR α mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

Blood (2012) 120 (10): 2098–2108.

https://doi.org/10.1182/blood-2012-01-407601

Published: 2012

Includes: Supplemental data

Journal Articles

Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710

Bayard L. Powell, MD, Barry K Moser, Ph.D., Wendy Stock, MD, Robert E. Gallagher, MD, Cheryl L Willman, MD, Richard M. Stone, MD, Jacob M. Rowe, MD, Steven E. Coutre, MD, James H. Feusner, M.D., John Gregory, MD, Stephen Couban, MD, FRCPC, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Richard A. Larson, MD

Blood (2011) 118 (21): 258.

https://doi.org/10.1182/blood.V118.21.258.258

Published: 2011

Journal Articles

Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129

Dan Douer, MD, Lynette Zickl, M.S., Charles A. Schiffer, M.D., Frederick R. Appelbaum, M.D., James H. Feusner, M.D., Lois E Shepherd, M.D., Cheryl L Willman, MD, Clara D. Bloomfield, MD, Jacob M. Rowe, MD, Peter H. Wiernik, M.D., Martin S. Tallman, MD

Blood (2011) 118 (21): 83.

https://doi.org/10.1182/blood.V118.21.83.83

Published: 2011

Journal Articles

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

Blood (2010) 116 (25): 5650–5659.

https://doi.org/10.1182/blood-2010-06-288613

Published: 2010

Journal Articles

FLT3 Mutations Are Prevalent and Are Significantly Associated with Induction Death In Pediatric Acute Promyelocytic Leukemia, a Report From the Children's Oncology Group

Matthew A. Kutny, MD, Barry K. Moser, PhD, John Gregory, MD, William G. Woods, MD, James H. Feusner, MD, Soheil Meshinchi, MD, PhD

Blood (2010) 116 (21): 753.

https://doi.org/10.1182/blood.V116.21.753.753

Published: 2010

Journal Articles

Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710.

Blood (2010) 116 (21): 1038.

https://doi.org/10.1182/blood.V116.21.1038.1038

Published: 2010

Journal Articles

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

Bayard L. Powell, Barry Moser, Wendy Stock, Robert E. Gallagher, Cheryl L. Willman, Richard M. Stone, Jacob M. Rowe, Steven Coutre, James H. Feusner, John Gregory, Stephen Couban, Frederick R. Appelbaum, Martin S. Tallman, Richard A. Larson

Blood (2010) 116 (19): 3751–3757.

https://doi.org/10.1182/blood-2010-02-269621

Published: 2010

Journal Articles

Response: “Lesser” ALL: should it be studied further as research budgets are diminishing?

James H. Feusner

Blood (2008) 111 (1): 469.

https://doi.org/10.1182/blood-2007-10-116004

Published: 2008

Journal Articles

Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710.

Bayard L. Powell, MD, Barry Moser, MD, Wendy Stock, MD, Robert E. Gallagher, MD, Cheryl L. Willman, MD, Richard M. Stone, MD, Jacob M. Rowe, MD, Steven Coutre, MD, James H. Feusner, MD, John Gregory, MD, Stephen Couban, MD, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Richard A. Larson, MD

Blood (2006) 108 (11): 566.

https://doi.org/10.1182/blood.V108.11.566.566

Published: 2006

Journal Articles

Outcomes in CCG-2961, a Children’s Cancer Group Phase III Trial for Untreated Acute Myeloid Leukemia (AML).

Beverly J. Lange, MD, Franklin O. Smith, MD, Patricia A. Dinndorf, MD, Carola A.S. Arndt, MD, Dorothy R. Barnard, MD, Kathryn Dusenbery, MD, Steven A. Feig, MD, James H. Feusner, MD, Sandra Luna-Fineman, MD, Joseph Neglia, MD, MPH, Nita L. Seibel, MD, Leonard Sender, MD, Kevin M. Shannon, MD, Margie Weiman, RN, Robert B. Gerbing, MA, Todd A. Alonzo, PhD

Blood (2005) 106 (11): 169.

https://doi.org/10.1182/blood.V106.11.169.169

Published: 2005

Journal Articles

Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.

Jacob M. Rowe, MD, Xiaochun Li, Peter A. Cassileth, MD, Frederick R. Appelbaum, MD, Charles A. Schiffer, MD, Peter H. Wiernik, MD, Mark R. Litzow, MD, Larry D. Cripe, MD, Hillard M. Lazarus, MD, Elisabeth Paietta, Ph.D, Gordon W. Dewald, MD, Howard J. Weinstein, MD, Angela K. Ogden, MD, William G. Woods, MD, Lois Shepherd, MD, James H. Feusner, MD, Clara D. Bloomfield, MD, Martin S. Tallman, MD

Blood (2005) 106 (11): 546.

https://doi.org/10.1182/blood.V106.11.546.546

Published: 2005

Journal Articles

Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.

Martin S. Tallman, MD, Haesook T. Kim, PhD, Charles A. Schiffer, MD, Frederick R. Appelbaum, MD, James H. Feusner, MD, Angela K. Ogden, MD, Lois Shepherd, MD, Cheryl L. Willman, MD, Clara D. Bloomfield, MD, Jacob M. Rowe, MD, Richard A. Larson, MD, Peter H. Wiernik, MD, Guillermo Martin, MD, Chelo Rayon, MD, Javier de la Serna, MD, Concha Rivas, MD, Jose D. Gonzalez-San Miguel, MD, Guillermo Deben, MD, Miguel A. Sanz, MD

Blood (2004) 104 (11): 394.

https://doi.org/10.1182/blood.V104.11.394.394

Published: 2004

NARROW

FLT3 Mutations in Pediatric Acute Promyelocytic Leukemia; A Report from the Children's Oncology Group AAML0631 Trial

Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631

Effect of Young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance)

A Comparison of Outcomes Between Adolescents and Young Adults (AYA) and Children with Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance)

Evaluation of ISTH DIC Score to Predict Significant Bleeding and Thrombosis Events in Pediatric Acute Promyelocytic Leukemia; A Report from the Children’s Oncology Group AAML0631 Trial

Arsenic Trioxide Is a Well Tolerated Consolidation Regimen in Children with Newly Diagnosed Acute Promyelocytic Leukemia; Toxicity Results of the Children’s Oncology Group AAML0631 Trial

Obesity Does Not Affect the Recurrence Free Survival Rates in Children Less Than 20 Years of Age in Acute Promyelocytic Leukemia (APL)

A Pilot Study to Assess Alterations in Trace Element Status in Pediatric Patients with Malignancies.

Treatment-influenced associations of PML-RAR α mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710

Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

FLT3 Mutations Are Prevalent and Are Significantly Associated with Induction Death In Pediatric Acute Promyelocytic Leukemia, a Report From the Children's Oncology Group

Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710.

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710

Response: “Lesser” ALL: should it be studied further as research budgets are diminishing?

Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710.

Outcomes in CCG-2961, a Children’s Cancer Group Phase III Trial for Untreated Acute Myeloid Leukemia (AML).

Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.

Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only